Core Viewpoint - Nurix Therapeutics, Inc. successfully closed an underwritten registered offering of 24,485,799 shares at $10.21 per share, raising gross proceeds of $250 million to fund clinical development and research activities [1][4]. Group 1: Offering Details - The offering included participation from both new and existing investors, highlighting strong support for the company's mission [2]. - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company acted as joint book-running managers for the offering [3]. - The securities were offered under a shelf registration statement previously filed with the SEC [5]. Group 2: Use of Proceeds - The net proceeds will primarily fund the clinical development of bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and explore potential autoimmune indications [4]. - Additional funds will support research and development activities to expand the pipeline and cover working capital and general corporate purposes [4]. Group 3: Company Overview - Nurix Therapeutics focuses on targeted protein degradation medicines for oncology and autoimmune diseases, with a pipeline that includes degraders of Bruton's tyrosine kinase (BTK) [8][9]. - The company is advancing multiple potentially first-in-class or best-in-class drug candidates and has collaborations with major pharmaceutical companies like Sanofi and Gilead [8][9].

Core Insights - Nurix Therapeutics, Inc. (NASDAQ:NRIX) is recognized as a small-cap stock with significant upside potential, particularly noted by billionaire Steve Cohen [1] - H.C. Wainwright has lowered its price target for Nurix from $34.00 to $33.00 while maintaining a Buy rating following the company's Q3 2025 earnings report [1][2] - The company reported a net loss of $1.03 per share, which was wider than the expected loss of $0.68, and generated revenue of $7.9 million, significantly below the projected $30 million [1][2] Financial Performance - Operating expenses exceeded expectations, with research and development (R&D) costs amounting to $86.1 million [2] - Despite the earnings miss, Nurix ended the quarter with $428.8 million in cash, which is projected to fund operations into early 2027 [2] Business Overview - Nurix Therapeutics is a biopharmaceutical company focused on discovering and developing targeted protein degradation (TPD) medicines aimed at treating cancer and immune disorders by modulating specific protein levels within cells [3]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Core Insights - Nurix Therapeutics is advancing a pipeline of innovative targeted protein degrader drugs in oncology and inflammation and immunology, each with best-in-class potential [2] Group 1: Lead Program Update - The call will focus on an important update regarding the lead program in chronic lymphocytic leukemia (CLL), specifically the drug bexobrutideg (NX-5948 or Bexdeg) [2] - Key discussions will include pivotal clinical development plans and new data supporting differentiation and dose selection for registrational trials of Bexdeg [2] Group 2: Partnered Pipeline Insights - New preclinical data from the partnered inflammation and immunology pipeline will be shared, specifically from the STAT6 and IRAK4 programs [3] - The STAT6 program is partnered with Sanofi, marking the first public disclosure of preclinical data profiling [3]

Summary of Nurix Therapeutics Conference Call (October 22, 2025) Company Overview - **Company**: Nurix Therapeutics (NasdaqGM:NRIX) - **Focus**: Development of targeted protein degrader drugs in oncology and inflammation/immunology (INI) with best-in-class potential Key Points on Lead Program: Vexer-Brutideg (NX-5948) - **Clinical Development**: - Initiation of pivotal trials in Chronic Lymphocytic Leukemia (CLL) has been announced, with regulatory alignment on dose selection for registrational purposes achieved with the FDA and other global authorities [4][5][39] - The selected dose for registrational trials is 600 mg once daily, based on favorable safety profiles observed in phase 1 studies [5][6] - The first pivotal trial, named the Daybreak study, is a single-arm phase 2 study targeting approximately 100 patients with relapsed refractory CLL [6][19] - **Efficacy Data**: - Objective response rate (ORR) of 80.9% observed in patients with high unmet medical need, including those with TP53 and/or BTK mutations [15][66] - Median time to response is less than two months, with durable treatment effects noted [16][17] - **Mechanism of Action**: - Vexdeg is effective against wild-type BTK and clinically relevant BTK mutations, addressing both the scaffolding function of BTK and promoting tumor cell growth [8][9] - Demonstrates catalytic action, degrading 10,000 to 20,000 BTK proteins per hour, which is a significant advantage over traditional inhibitors [8] - **Regulatory Designations**: - Vexdeg has received fast-track status in the U.S. and PRIME designation in the EU, facilitating expedited development [4][12] Pipeline Developments - **Partnerships**: - Nurix has partnered with Sanofi for the STAT-6 program and Gilead Sciences for the IRAK4 program, with potential for co-development in the U.S. [2][32] - New preclinical data for both partnered programs has been disclosed, highlighting their differentiation potential [2][32] - **Future Studies**: - A confirmatory phase 3 trial is planned for the first half of 2026, targeting a broader patient population [20][39] - Combination studies with other agents are also being explored to enhance patient outcomes [21] Financial Position - **Cash Position**: - Nurix anticipates a pro forma cash balance of $678 million, providing a runway into 2028 [39] Market Context - **CLL Market**: - Approximately 120,000 patients initiate new treatment each year across major markets, with 50% in the second line or later [18] - The company aims to address the needs of relapsed and refractory CLL patients, particularly those who are triple-exposed to existing therapies [19][61] Competitive Landscape - **Differentiation**: - Vexdeg is positioned as a potentially best-in-class BTK degrader, with superior potency, mutation coverage, and selectivity compared to existing therapies [25][26][76] - The market for degraders is expected to be large, with potential for multiple drugs to coexist, but Nurix believes Vexdeg will capture significant market share due to its profile [76] Conclusion - Nurix Therapeutics is advancing its lead program Vexer-Brutideg towards pivotal trials in CLL, with promising efficacy data and strong regulatory support. The company is well-positioned financially and strategically to capitalize on the growing market for targeted protein degraders in oncology and inflammation.

Bexobrutideg Investor Update Investor Presentation October 2025 Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any infor ...

Core Viewpoint - Nurix Therapeutics, Inc. has announced the pricing of its underwritten registered offering of 24,485,799 shares at $10.21 per share, aiming to raise approximately $250 million for clinical development and research activities [1][4]. Group 1: Offering Details - The offering consists of 24,485,799 shares priced at $10.21 each, with expected gross proceeds of $250 million before expenses [1]. - The offering is set to close on or about October 23, 2025, pending customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as General Atlantic and Redmile Group [2]. Group 2: Use of Proceeds - Nurix intends to use the net proceeds primarily for clinical development of drug candidates, including bexobrutideg (NX-5948) for chronic lymphocytic leukemia (CLL) and potential autoimmune indications [4]. - Additional uses include funding research and development to expand the pipeline, as well as for working capital and general corporate purposes [4]. Group 3: Management and Registration - J.P. Morgan Securities LLC, Jefferies LLC, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering [3]. - The offering is made under a shelf registration statement previously filed with the SEC, which was declared effective on June 11, 2024 [5].

Core Insights - Nurix Therapeutics has initiated the DAYBreak clinical trial for bexobrutideg, a pivotal Phase 2 study targeting relapsed or refractory chronic lymphocytic leukemia (r/r CLL) [1][4] - The 600 mg once-daily dose of bexobrutideg has been cleared by global regulators, including the FDA and EMA, following data analysis from a Phase 1b study [2][4] - The company plans to conduct a Phase 3 confirmatory trial in the first half of 2026, comparing bexobrutideg to other treatment options for r/r CLL patients [5][6] Company Developments - Nurix is transitioning to a pivotal-stage company with the initiation of the DAYBreak study, marking a significant milestone for bexobrutideg [4] - The DAYBreak study will enroll patients who have progressed after treatment with various BTK inhibitors, aiming to address unmet medical needs [4][6] - The company has generated substantial data supporting bexobrutideg's potential as a best-in-class BTK degrader [7][8] Clinical Trial Details - The DAYBreak trial is a single-arm Phase 2 study evaluating the efficacy of bexobrutideg in patients with r/r CLL [1][4] - A randomized Phase 3 trial is planned to compare bexobrutideg monotherapy against other treatment regimens in patients whose disease has progressed on prior therapies [5][6] - The favorable safety profile of the 600 mg dose is expected to optimize therapeutic effects for patients [6] Investor Engagement - Nurix will host an investor webcast to provide updates on the program and discuss new preclinical data supporting bexobrutideg [3][9] - The webcast will include highlights of unpublished data demonstrating superior degradation potency and selectivity of bexobrutideg [8][10]

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing a disease control rate (DCR) of 49.3% [2][3] - Notable clinical activity included reductions in tumor-specific biomarkers, long-term stable disease, and a confirmed partial response in a patient with micro-satellite stable colorectal cancer [2][3] - The most significant reductions in prostate-specific antigen (PSA) were observed in patients receiving BID dosing, with 6 out of 13 patients achieving PSA reductions of ≥50% [2] Safety Profile - NX-1607 exhibited a tolerable safety profile, comparable to approved immuno-oncology agents, with most adverse events being Grade 2 or less [3] - Immune-related adverse events were observed in 6 patients, indicating on-target immune activation similar to PD-1/PD-L1 therapies [3] Future Development - The company plans to further explore the therapeutic potential of NX-1607, particularly in indications where current immunotherapies have shown limited efficacy, such as MSS colorectal cancer and metastatic prostate cancer [4]

Core Insights - NX-1607 is a first-in-class oral inhibitor of CBL-B, demonstrating on-target peripheral immune activation and anti-tumor activity in heavily pretreated patients with advanced solid tumors [1][2][4] - The clinical data presented at ESMO 2025 supports the initiation of expansion cohorts for further evaluation of NX-1607 as a monotherapy or in combination therapies [1][2] Company Overview - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [7] - The company is advancing multiple clinical and preclinical programs, including NX-1607 and bexobrutideg, an oral BTK degrader [7] Clinical Data Summary - In a Phase 1a study, 82 patients with various solid tumors were treated with NX-1607 across different dosing regimens, showing dose-dependent exposure and clinical activity [2][3] - The disease control rate (DCR) was reported at 49.3%, with notable reductions in tumor-specific biomarkers such as PSA and CEA [2][3] - The treatment was well-tolerated, with most adverse events being Grade 2 or less, and immune-related adverse events indicating on-target immune activation [3][4] Therapeutic Potential - NX-1607 targets a previously unaddressed pathway in immune regulation, affecting multiple immune cell types, which may enhance its efficacy in treating solid tumors [2][6] - The results are particularly promising for tumor types like micro-satellite stable colorectal cancer and metastatic prostate cancer, where current immunotherapies have shown limited efficacy [4]